
The company will continue to experiment with microgravity-derived experiments.

The company will continue to experiment with microgravity-derived experiments.

TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.

The drug is currently in Phase 1 clinical trials for gastric cancer treatments.